JP2024517618A5 - - Google Patents

Info

Publication number
JP2024517618A5
JP2024517618A5 JP2023563172A JP2023563172A JP2024517618A5 JP 2024517618 A5 JP2024517618 A5 JP 2024517618A5 JP 2023563172 A JP2023563172 A JP 2023563172A JP 2023563172 A JP2023563172 A JP 2023563172A JP 2024517618 A5 JP2024517618 A5 JP 2024517618A5
Authority
JP
Japan
Prior art keywords
cells
cell
optionally
lymphoma
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517618A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024725 external-priority patent/WO2022221478A1/en
Publication of JP2024517618A publication Critical patent/JP2024517618A/ja
Publication of JP2024517618A5 publication Critical patent/JP2024517618A5/ja
Pending legal-status Critical Current

Links

JP2023563172A 2021-04-14 2022-04-14 Ha-2抗原を認識する結合タンパク質及びその使用 Pending JP2024517618A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163174818P 2021-04-14 2021-04-14
US63/174,818 2021-04-14
US202163215760P 2021-06-28 2021-06-28
US63/215,760 2021-06-28
US202163288078P 2021-12-10 2021-12-10
US63/288,078 2021-12-10
US202263329560P 2022-04-11 2022-04-11
US63/329,560 2022-04-11
PCT/US2022/024725 WO2022221478A1 (en) 2021-04-14 2022-04-14 Binding proteins recognizing ha-2 antigen and uses thereof

Publications (2)

Publication Number Publication Date
JP2024517618A JP2024517618A (ja) 2024-04-23
JP2024517618A5 true JP2024517618A5 (cg-RX-API-DMAC7.html) 2025-04-22

Family

ID=83640691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563172A Pending JP2024517618A (ja) 2021-04-14 2022-04-14 Ha-2抗原を認識する結合タンパク質及びその使用

Country Status (11)

Country Link
US (1) US20240197877A1 (cg-RX-API-DMAC7.html)
EP (1) EP4322971A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517618A (cg-RX-API-DMAC7.html)
KR (1) KR20230170704A (cg-RX-API-DMAC7.html)
AU (2) AU2022204581B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023021034A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215276A1 (cg-RX-API-DMAC7.html)
IL (1) IL307429A (cg-RX-API-DMAC7.html)
MX (1) MX2023012111A (cg-RX-API-DMAC7.html)
TW (1) TW202313670A (cg-RX-API-DMAC7.html)
WO (1) WO2022221478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024118640A2 (en) * 2022-11-29 2024-06-06 Bluesphere Bio, Inc. T cell receptors targeting minor histocompatibility antigen ha-2
WO2024148212A2 (en) * 2023-01-06 2024-07-11 The Trustees Of The University Of Pennsylvania T cell receptors directed to sox2 protein
KR20260013471A (ko) 2023-05-18 2026-01-28 클레이드 쎄라퓨틱스 인코포레이티드 세포 치료법에 대한 자연살해세포 세포독성 억제
WO2025217028A1 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
WO2025217035A2 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds
WO2026122679A1 (en) * 2024-12-06 2026-06-11 Tscan Therapeutics, Inc. Binding proteins recognizing cd45 immunogenic peptides and uses thereof
WO2026128475A1 (en) 2024-12-09 2026-06-18 Century Therapeutics, Inc. Genetically engineered induced pluripotent stem cells and effector cells derived therefrom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318842T1 (de) * 1995-07-25 2006-03-15 Univ Leiden Antigenische ha-2 peptide
WO2003054152A2 (en) * 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
SI2755997T1 (sl) * 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
CN112566698A (zh) * 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
EP3670530A1 (en) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
BR112021017744A2 (pt) * 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
US20220213167A1 (en) * 2019-05-03 2022-07-07 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof

Similar Documents

Publication Publication Date Title
AU2021200388B2 (en) Methods of isolating T cell receptors having antigenic specificity for a cancer specific mutation
US12391742B2 (en) Anti-KRAS-G12D T cell receptors
JP7270001B2 (ja) Mhcクラスii拘束性mage-a3を認識するt細胞受容体
Beyar-Katz et al. Novel approaches to acute myeloid leukemia immunotherapy
JP2023549765A5 (cg-RX-API-DMAC7.html)
JP7770188B2 (ja) 養子細胞療法のための標的共刺激を提供する受容体
MacDonald et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor
Behar et al. Diverse TCRs recognize murine CD1
Mingari et al. HLA-class I-specific inhibitory receptors in human cytolytic T lymphocytes: molecular characterization, distribution in lymphoid tissues and co-expression by individual T cells.
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
CA3144070A1 (en) T cell receptors recognizing r175h or y220c mutation in p53
CN115747156A (zh) 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖
US12365717B2 (en) Specific t cell receptors against epitopes of mutant MYD88L265P protein for adoptive T cell therapy
JP2024546018A5 (cg-RX-API-DMAC7.html)
JP2024515646A5 (cg-RX-API-DMAC7.html)
Jaigirdar et al. A high avidity WT1 reactive T cell receptor mediates recognition of peptide and processed antigen but not naturally occurring WT1 positive tumor cells
Zambello et al. Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes
Chen et al. Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system
AU2016329542C1 (en) TCR and uses thereof
JP2025516264A5 (cg-RX-API-DMAC7.html)
Chmielowski et al. In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities
TW202406569A (zh) 多重t細胞受體組合物、組合療法及其用途
US20240360236A1 (en) Methods for targeted immunotherapy of acute myeloid leukemia (aml)
EP4491630A1 (en) T-cell receptor for acute myeloid leukemia (aml)
EP4223782A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer